Hologic stock (US4364401012): Joins S&P SmallCap 600 ahead of May 14

Hologic set for inclusion in S&P SmallCap 600 index effective May 14, 2026, potentially boosting visibility and liquidity for US investors.

Hologic will join the S&P SmallCap 600 index effective before trading opens on May 14, 2026, according to index tracking data on Pluang as of May 2026. This addition highlights the company's role in women's health diagnostics amid ongoing market adjustments. The stock trades on Nasdaq under HOLX.

As of: 05/12/2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Hologic, Inc.
• Sector/industry: Medical devices / Women's health
• Headquarters/country: United States
• Core markets: North America, Europe
• Key revenue drivers: Diagnostics, imaging systems
• Home exchange/listing venue: Nasdaq (HOLX)
• Trading currency: USD

Hologic: core business model

Hologic develops, manufactures and sells medical imaging systems, surgical products and diagnostics primarily focused on women's health. The company offers breast health solutions including mammography and biopsy systems, as well as diagnostics for infectious diseases. This focus positions Hologic as a key player for US healthcare providers serving the mammography screening market.

Revenue stems from equipment sales, service contracts and consumables. Hologic's innovations target precision diagnostics, with products like the Genius 3D Mammography system used widely in US breast cancer screening programs, according to company materials.

Main revenue and product drivers for Hologic

Breast health solutions account for the largest revenue share, driven by imaging and biopsy systems. In recent periods, diagnostics grew through molecular testing platforms amid demand for women's health screenings. Surgical products for gynecological procedures provide recurring income via disposables.

Hologic's Affirm Contrast Biopsy Software received CE marking in February 2025, enhancing precision prostate diagnostics capabilities, per BioSpace as of 2025. This expands addressable markets beyond core breast health.

Industry trends and competitive position

The medical imaging sector sees rising demand for AI-enhanced diagnostics and minimally invasive biopsies, benefiting Hologic's portfolio. Competitors include GE Healthcare and Siemens Healthineers, but Hologic holds a strong US foothold in mammography with over 50% market share in digital systems per dated sector reports.

Why Hologic matters for US investors

Hologic's Nasdaq listing and exposure to the US healthcare system, which accounts for nearly half of global medical device spending, make it relevant for domestic portfolios. Index inclusion like S&P SmallCap 600 could attract passive inflows, enhancing liquidity for US traders.

Conclusion

Hologic's upcoming S&P SmallCap 600 inclusion underscores its stable position in women's health medtech. With products addressing key US screening needs, the company navigates sector trends toward precision diagnostics. Investors track index effects and product updates for market implications.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.